|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
Q4 FY2021
As of Jun 30, 2021
|
Q3 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current asset - cash | |||||||||
| Current assets: | |||||||||
| Prepayments | |||||||||
| Cash | |||||||||
| Total current assets | |||||||||
| Cash and investments held in trust account | |||||||||
| TOTAL ASSETS | |||||||||
| LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT | |||||||||
| Current liabilities: | |||||||||
| Accrued liabilities and other payable | |||||||||
| Notes payable | |||||||||
| Amount due to related parties | |||||||||
| Total current liabilities | |||||||||
| Warrant liabilities | |||||||||
| Deferred underwriting compensation | |||||||||
| TOTAL LIABILITIES | |||||||||
| Ordinary shares, subject to possible redemption: 1,745,613 and 5,750,000 shares (at redemption value of $10.76 and $10.22 per share), respectively | |||||||||
| Shareholders’ deficit: | |||||||||
| Ordinary shares; no par value; unlimited shares authorized; 1,816,250 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively | |||||||||
| Accumulated other comprehensive income | |||||||||
| Accumulated deficit | |||||||||
| Total shareholders’ deficit | |||||||||
| TOTAL LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT |
Loading...
